1. Home
  2. RTO vs VTRS Comparison

RTO vs VTRS Comparison

Compare RTO & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rentokil Initial plc

RTO

Rentokil Initial plc

HOLD

Current Price

$30.74

Market Cap

15.9B

ML Signal

HOLD

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$13.08

Market Cap

17.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RTO
VTRS
Founded
1925
1961
Country
United Kingdom
United States
Employees
65632
30000
Industry
Business Services
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.9B
17.2B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
RTO
VTRS
Price
$30.74
$13.08
Analyst Decision
Strong Buy
Buy
Analyst Count
4
4
Target Price
$35.00
$13.00
AVG Volume (30 Days)
1.7M
9.6M
Earning Date
03-09-2026
05-07-2026
Dividend Yield
1.67%
3.56%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$14,299,900,000.00
Revenue This Year
$17.39
$4.45
Revenue Next Year
$6.25
$1.79
P/E Ratio
$222.16
N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.60
$6.85
52 Week High
$33.47
$16.47

Technical Indicators

Market Signals
Indicator
RTO
VTRS
Relative Strength Index (RSI) 45.57 32.97
Support Level $29.31 $12.92
Resistance Level $32.79 $13.49
Average True Range (ATR) 0.72 0.42
MACD -0.00 -0.19
Stochastic Oscillator 47.16 4.82

Price Performance

Historical Comparison
RTO
VTRS

About RTO Rentokil Initial plc

Rentokil Initial is the largest global provider of route-based pest control and commercial hygiene services, operating in over 90 countries, with its largest operations in the United States following the acquisition of Terminix. The group also offers a range of specialist route-based services, including office and commercial space plant care, property care, and workwear rentals. The group serves a diverse client base of global food producers, hotel chains, industrial goods companies, restaurants, and individual residential customers.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: